Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures.

Proniras has received an $89.5 million award from HHS’s Biomedical

Read the full 300 word article

User Sign In